Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

Becton Dickinson (BDX) reported positive 9-month results from its AGILITY trial for the Revello Vascular Covered Stent, meeting its primary endpoint. The company has seen a 20.28% share price increase over 90 days, despite a 6.25% year-to-date decline. Analysts suggest the stock is 7% undervalued at $182.75, with a fair value estimate of $195.67. Recent developments include a U.S. manufacturing partnership, leadership changes, and a product recall.

Becton, Dickinson and Company (BD) reported nine-month data from the AGILITY trial of its Revello Vascular Covered Stent, showing a 2.8% failure rate for the primary endpoint in iliac artery disease patients. The trial met its safety and effectiveness goals, with 97.2% primary patency and 98.3% freedom from revascularization. The stent is CE-marked in Europe but remains investigational in the US. BD aims to further characterize the stent's performance as follow-up continues.

BD (BDX) reported nine-month results from the iliac cohort of the AGILITY trial for its Revello Vascular Covered Stent, meeting primary endpoints with a 2.8% failure rate. The study showed 97.2% primary patency and 98.3% freedom from revascularization, with no device-related deaths. The stent is CE marked but investigational in the U.S. BD completed enrollment in the study’s superficial femoral and proximal popliteal artery cohort in August.

BD (NYSE: BDX) reported positive nine-month results from the AGILITY trial for its Revello™ Vascular Covered Stent, showing high vessel patency and low reintervention rates in treating iliac artery disease. The study met its primary endpoint with a 2.8% failure rate, and patients showed improved mobility and symptoms. The trial is ongoing, with follow-up through 36 months. The device is CE marked but remains investigational in the U.S.

Becton Dickinson (BDX) plans a $19B U.S. investment over several years, including $3B for manufacturing expansion, under a tariff relief agreement with the federal government. The company aims to increase U.S. production of essential medical consumables, with all needles made domestically. Tariff relief is contingent on meeting agreed milestones. The Trump administration has yet to finalize the tariff rule.

Becton Dickinson agreed to invest $19 billion in the U.S. over several years, including $3 billion for expanding domestic manufacturing, in exchange for future tariff relief. The company plans to increase U.S. production of medical consumables and needles, aiming for 80% domestic supply. President Trump announced medical device tariffs by year-end. The financial impact of the deal is not yet quantified.